164 related articles for article (PubMed ID: 16633004)
1. High eIF4E, VEGF, and microvessel density in stage I to III breast cancer.
Byrnes K; White S; Chu Q; Meschonat C; Yu H; Johnson LW; Debenedetti A; Abreo F; Turnage RH; McDonald JC; Li BD
Ann Surg; 2006 May; 243(5):684-90; discussion 691-2. PubMed ID: 16633004
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer.
Wolfort R; de Benedetti A; Nuthalapaty S; Yu H; Chu QD; Li BD
Surgery; 2006 Aug; 140(2):161-9. PubMed ID: 16904965
[TBL] [Abstract][Full Text] [Related]
3. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer.
McClusky DR; Chu Q; Yu H; Debenedetti A; Johnson LW; Meschonat C; Turnage R; McDonald JC; Abreo F; Li BD
Ann Surg; 2005 Oct; 242(4):584-90; discussion 590-2. PubMed ID: 16192819
[TBL] [Abstract][Full Text] [Related]
4. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer.
Zhou S; Wang GP; Liu C; Zhou M
BMC Cancer; 2006 Sep; 6():231. PubMed ID: 17010208
[TBL] [Abstract][Full Text] [Related]
5. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.
Byrnes KW; DeBenedetti A; Holm NT; Luke J; Nunez J; Chu QD; Meschonat C; Abreo F; Johnson LW; Li BD
J Am Coll Surg; 2007 May; 204(5):925-33; discussion 933-4. PubMed ID: 17481512
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression.
Li BD; McDonald JC; Nassar R; De Benedetti A
Ann Surg; 1998 May; 227(5):756-6l; discussion 761-3. PubMed ID: 9605667
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome.
Li BD; Gruner JS; Abreo F; Johnson LW; Yu H; Nawas S; McDonald JC; DeBenedetti A
Ann Surg; 2002 May; 235(5):732-8; discussion 738-9. PubMed ID: 11981220
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of eukaryotic initiation factor 4E is correlated with increased risk for systemic dissemination in node-positive breast cancer patients.
Yin X; Kim RH; Sun G; Miller JK; Li BD
J Am Coll Surg; 2014 Apr; 218(4):663-71. PubMed ID: 24491247
[TBL] [Abstract][Full Text] [Related]
9. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer.
Holm N; Byrnes K; Johnson L; Abreo F; Sehon K; Alley J; Meschonat C; Md QC; Li BD
Ann Surg Oncol; 2008 Nov; 15(11):3207-15. PubMed ID: 18719964
[TBL] [Abstract][Full Text] [Related]
10. TLK1B is elevated with eIF4E overexpression in breast cancer.
Norton KS; McClusky D; Sen S; Yu H; Meschonat C; Debenedetti A; Li BD
J Surg Res; 2004 Jan; 116(1):98-103. PubMed ID: 14732354
[TBL] [Abstract][Full Text] [Related]
11. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of eIF4E reduction after neoadjuvant therapy in breast cancer.
Hiller DJ; Chu Q; Meschonat C; Panu L; Burton G; Li BD
J Surg Res; 2009 Oct; 156(2):265-9. PubMed ID: 19665145
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma.
Li BD; Liu L; Dawson M; De Benedetti A
Cancer; 1997 Jun; 79(12):2385-90. PubMed ID: 9191527
[TBL] [Abstract][Full Text] [Related]
14. Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
Heikkinen T; Korpela T; Fagerholm R; Khan S; Aittomäki K; Heikkilä P; Blomqvist C; Carpén O; Nevanlinna H
Breast Cancer Res Treat; 2013 Aug; 141(1):79-88. PubMed ID: 23974830
[TBL] [Abstract][Full Text] [Related]
15. Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome.
Chen CN; Hsieh FJ; Cheng YM; Lee PH; Chang KJ
J Surg Oncol; 2004 Apr; 86(1):22-7. PubMed ID: 15048676
[TBL] [Abstract][Full Text] [Related]
16. Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray.
Yang SX; Hewitt SM; Steinberg SM; Liewehr DJ; Swain SM
Oncol Rep; 2007 Feb; 17(2):281-7. PubMed ID: 17203162
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients.
Ludovini V; Sidoni A; Pistola L; Bellezza G; De Angelis V; Gori S; Mosconi AM; Bisagni G; Cherubini R; Bian AR; Rodinò C; Sabbatini R; Mazzocchi B; Bucciarelli E; Tonato M; Colozza M
Breast Cancer Res Treat; 2003 Sep; 81(2):159-68. PubMed ID: 14572158
[TBL] [Abstract][Full Text] [Related]
18. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
19. Microvessel density and vascular endothelial growth factor expression in infiltrating lobular mammary carcinoma.
Chhieng DC; Tabbara SO; Marley EF; Talley LI; Frost AR
Breast J; 2003; 9(3):200-7. PubMed ID: 12752628
[TBL] [Abstract][Full Text] [Related]
20. [Significance of microvascular density and vascular endothelial growth factor in breast cancer].
Li J; Song ST; Jiang ZF; Liu XQ; Yan LD
Zhonghua Zhong Liu Za Zhi; 2003 Mar; 25(2):145-8. PubMed ID: 12795840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
